154
Participants
Start Date
March 16, 2018
Primary Completion Date
October 15, 2020
Study Completion Date
December 31, 2025
Durvalumab
Durvalumab 1500 mg IV q4w
Olaparib
Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
Placebo
Matching placebo for oral tablet BID
Research Site, Taipei
Research Site, Taipei
Research Site, Taoyuan
Research Site, Tainan City
Research Site, Kaohsiung City
Research Site, Seoul
Research Site, Taipei
Research Site, New York
Research Site, The Bronx
Research Site, New Hyde Park
Research Site, Santiago de Compostela
Research Site, Philadelphia
Research Site, Incheon
Research Site, Madrid
Research Site, Málaga
Research Site, Tampa
Research Site, St. Petersburg
Research Site, Fort Myers
Research Site, Birmingham
Research Site, Nashville
Research Site, Louisville
Research Site, Taichung
Research Site, Goodyear
Research Site, Tacoma
Research Site, Hanoi
Research Site, Moscow
Research Site, Moscow
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Saint Petersburg
Research Site, Novosibirsk
Research Site, Omsk
Research Site, Ho Chi Minh City
Research Site, Greater Sudbury
Research Site, Hamilton
Research Site, Newmarket
Research Site, Toronto
Research Site, Montreal
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Madrid
Research Site, Kaohsiung City
Lead Sponsor
AstraZeneca
INDUSTRY